A cheaper and effective approach to clinical CAR-T manufacturing

In as post by Elena Sotillo on Linkedin, it says, “Since joining Crystal Mackall lab, Hyatt Balke-Want wanted to develop a robust viral-free platform that would yield enough CAR-T cells to treat patients. Under the expert eye of Steven Feldman he developed HITI, a system based on nanoplasmid DNA to specifically knock-in CAR via homology-independent targeted insertion, together with a selection marker. Upon enrichment of the engineered population, he achieved ~80% pure CAR-T cells at doses therapeutically relevant and without any evidence of off-target genomic toxicity.

A cheaper and effective approach to clinical CAR-T manufacturing!”

For details: Click here

Source: Elena Sotillo/Linkedin